Skip to main content

Table 5 Univariate and multivariate associations with late grade 3 genitourinary toxicity

From: Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer

Variables

Associated level

Late grade 3 GU toxicity

  

Hazard ratio (95% CI)

p-value

Univariate analysis

   

Age (years)

Continuous

1.031 (0.921-1.154)

0.596

Risk group*

Intermediate

0.659 (0.079-5.481)

0.699

Prostate volume#

Continuous

0.928 (0.835-1.032)

0.170

Number of Applicators

Continuous

1.247 (0.906-1.718)

0.176

PTV volume (cm3)

Continuous

1.014 (0.974-1.056)

0.504

PTV V100 (%)

Continuous

>1000 (0.000- > 1000)

0.371

PTV D90 (Gy)

Continuous

83.476 (0.019- > 1000)

0.301

Urethral volume (cm3)

Continuous

41.143 (2.754-614.621)

0.007

Urethral D1 (Gy)

Continuous

6.946 (0.000- > 1000)

0.692

Urethral V100 (cm3)

Continuous

183.29 (6.785- > 1000)

0.002

Urethral V120 (cm3)

Continuous

926.461 (2.653- > 1000)

0.022

Urethral V125 (cm3)

Continuous

405.747 (0.249- > 1000)

0.111

Acute grade 3 GU toxicity

Yes

7.846 (0.876-70.307)

0.066

Multivariate analysis

   

Urethral volume (cm3)

Continuous

338.940 (9.502- > 1000)

0.001

Urethral V100 (cm3)

Continuous

-

 

Urethral V120 (cm3)

Continuous

5778.111 (14.398- > 1000)

0.005

Acute grade 3 GU toxicity

Yes

-

 
  1. Abbreviations: GU genitourinary, PTV planning target volume, PTV V 100 percentage of PTV receiving ≥100% of prescribed dose, D 90 dose administered to 90% of the PTV, Urethral V 100 -V150 absolute urethral volume that received a dose ≥100%, 120%, 125%, 150% of the prescribed dose, Urethral D 1 maximal dose that encompass 1% of the urethral volume, *according to the National Comprehensive Cancer Network ( NCCN), #pre-treatment, ADT androgen deprivation therapy.
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us